Mithra and Adamed Sign Commercialization Agreement for Myring™ in the Czech Republic

  • Mithra grants non-exclusive 10-year license for vaginal contraception ring MyringTM to Adamed for commercialization in the Czech Republic
  • Agreement follows US and Austrian license granted to Mayne Pharma and Gynial, respectively
  • MyringTM to be manufactured at Mithra CDMO

Liège, Belgium, 27 December 2017 –  Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announced a non-exclusive, 10-year license and supply agreement with Adamed Group (Adamed), for the commercialization of MyringTM, Mithra’s combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA), in the Czech Republic. Adamed is a Polish pharmaceutical and biotechnology company with a focus on gynaecology. Financial details of the agreement were not disclosed.

Mithra Announces Injectables Agreement with GSP

  • Mithra closes contracts with leading generics player GSP for development and supply of 4 hormonal injectables
  • Contracts should allow for European and US GMP approval of injectable section at Mithra CDMO
  • Strong validation by reputable partner of know-how and capabilities of Mithra CDMO

Liège, Belgium, 14 December 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces an agreement with GSP for the injectables section of the Mithra CDMO. The umbrella agreement comprises the development and production of four products. GSP (Generic Speciality Pharma), based in Northern Dublin (Ireland), is a leading player in generic healthcare products. The company, part of the Alter Pharma group, works with 3rd party manufacturers in a large number of geographies and outlicenses its product portfolio to partners worldwide.

Mithra Finalizes Estelle® Contract with Brazilian Women’s Health Leader Libbs

  • Mithra is eligible for a EUR 20 million upfront milestone payment, with EUR 14 million to be received in 2017
  • 20-year contract grants Libbs an exclusive commercial license as well as manufacturing rights for Estelle® in Brazil, in addition to a cost-effective alternative supply option for key APIs (Active Pharmaceutical Ingredients)
  • Contract forms part of Mithra’s strategy to realize full potential of pipeline programs through global partnerships with leaders in Women’s Health

Liège, Belgium, 11 December 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, is pleased to announce finalization and signature of the contract with Libbs, the Women’s Health leader in Brazil, for an exclusive license to Estelle® in Brazil. This follows the binding Heads of Terms announced in September 2017. Estelle® is Mithra’s novel oral contraceptive product candidate composed of 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP). Estelle® is currently in Phase III trials in the US and Canada as well as in Europe and Russia, with top line results expected in Q3 2018 and Q1 2019, respectively.

Mithra Announces Valorization of French Subsidiary

Liège, Belgium, 7 December 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces that it successfully divested its French affiliate, Mithra France.